A randomized, double blind, placebo controlled phase 3 trial of immunotherapy with autologous antigen presenting cells loading with PA2024 (Provenge, APC8015) in men with metastatic androgen independent prostatic adenocarcinoma

Trial Profile

A randomized, double blind, placebo controlled phase 3 trial of immunotherapy with autologous antigen presenting cells loading with PA2024 (Provenge, APC8015) in men with metastatic androgen independent prostatic adenocarcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Sipuleucel-T (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms IMPACT
  • Sponsors Dendreon Corporation
  • Most Recent Events

    • 18 Feb 2017 Results of survival outcomes from three phase III studies including this study presented at the 2017 Genitourinary Cancers Symposium
    • 18 Feb 2017 Results of four sipuleucel-T trials (STAND, IMPACT, STAMP, and STRIDE) presented at the 2017 Genitourinary Cancers Symposium
    • 20 May 2014 According to a Dendreon Corporation media release, the results of this and two other trials (700195649 and 70036006) will be presented at the 2014 American Urological Association Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top